d(GC) - Association of Biotechnology and Pharmacy
d(GC) - Association of Biotechnology and Pharmacy
d(GC) - Association of Biotechnology and Pharmacy
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Current Trends in <strong>Biotechnology</strong> <strong>and</strong> <strong>Pharmacy</strong><br />
Vol. 6 (2) 119-144 April 2012, ISSN 0973-8916 (Print), 2230-7303 (Online)<br />
62. NCBI-GeneTests. Dihydropyrimidine<br />
Dehydrogenase Deficiency. http://<br />
www.ncbi.nlm.nih.gov/sites/GeneTests/lab/<br />
clinical_disease_id/234208?db=genetests<br />
Accessed 31, Jan 2012<br />
63. Wheeler, D., Dunn, E. <strong>and</strong> Harari, P. (2010).<br />
Underst<strong>and</strong>ing resistance to EGFR<br />
inhibitors - impact on future treatment<br />
strategies. Nat Rev Clin Oncol, 7: 493-507.<br />
64. Prenen, H., Tejpar, S., <strong>and</strong> Van Cutsem, E.<br />
(2010). New strategies for treatment <strong>of</strong><br />
KRAS mutant metastatic colorectal cancer.<br />
Clin Cancer Res, 16: 2921-2926.<br />
65. US-FDA. DakoCytomation EGFR<br />
66.<br />
pharmDx(TM) - P030044. http://<br />
www.fda.gov/MedicalDevices/<br />
Products<strong>and</strong>MedicalProcedures/<br />
DeviceApprovals<strong>and</strong>Clearances/Recently-<br />
ApprovedDevices/ucm081222.htm<br />
Accessed 31, Jan 2012<br />
Chung, K.Y., Shia, J., Kemeny, N.E., Shah,<br />
M., Schwartz, G.K., Tse, A., Hamilton, A.,<br />
Pan, D., Schrag, D., Schwartz, L., Klimstra,<br />
D.S., Fridman, D., Kelsen, D.P., <strong>and</strong> Saltz,<br />
L.B. (2005). Cetuximab shows activity in<br />
colorectal cancer patients with tumors that<br />
do not express the epidermal growth factor<br />
receptor by immunohistochemistry. J Clin<br />
Oncol, 23: 1803-10.<br />
67. Karapetis, C.S., Khambata-Ford, S.,<br />
Jonker, D.J., O’Callaghan, C.J., Tu, D.,<br />
Tebbutt, N.C., Simes, R.J., Chalchal, H.,<br />
Shapiro, J.D., Robitaille, S., Price, T.J.,<br />
Shepherd, L., Au, H.J., Langer, C., Moore,<br />
M.J., <strong>and</strong> Zalcberg, J.R. (2008). K-ras<br />
mutations <strong>and</strong> benefit from cetuximab in<br />
advanced colorectal cancer. N Engl J Med,<br />
359: 1757-65.<br />
68. Amado, R.G., Wolf, M., Peeters, M., Van<br />
Cutsem, E., Siena, S., Freeman, D.J., Juan,<br />
T., Sikorski, R., Suggs, S., Radinsky, R.,<br />
Patterson, S.D. <strong>and</strong> Chang, D.D. (2008).<br />
Wild-type KRAS is required for<br />
panitumumab efficacy in patients with<br />
Rebecca E. Smith <strong>and</strong> Juan Miguel Pascale<br />
140<br />
69.<br />
metastatic colorectal cancer. J Clin Oncol,<br />
26: 1626-34.<br />
Eng, C. (2010). The evolving role <strong>of</strong><br />
monoclonal antibodies in colorectal cancer:<br />
early presumptions <strong>and</strong> impact on clinical<br />
trial development. Oncologist, 15: 73-84.<br />
70. Allegra, C.J., Jessup, J.M., Somerfield,<br />
M.R., Hamilton, S.R., Hammond, E.H.,<br />
Hayes, D.F., McAllister, P.K., Morton, R.F.,<br />
<strong>and</strong> Schilsky, R.L. (2009). American Society<br />
<strong>of</strong> Clinical Oncology provisional clinical<br />
opinion: testing for KRAS gene mutations<br />
in patients with metastatic colorectal<br />
carcinoma to predict response to antiepidermal<br />
growth factor receptor<br />
71.<br />
monoclonal antibody therapy. J Clin Oncol,<br />
27: 2091-6.<br />
Saridaki, Z., Georgoulias, V., <strong>and</strong><br />
Souglakos, J. (2010). Mechanisms <strong>of</strong><br />
resistance to anti-EGFR monoclonal<br />
antibody treatment in metastatic colorectal<br />
cancer. World J Gastroenterol, 16: 1177-<br />
1187.<br />
72. US-FDA. cobas® 4800 BRAF V600<br />
Mutation Test - P110020. http://<br />
www.fda.gov/MedicalDevices/<br />
Products<strong>and</strong>MedicalProcedures/<br />
DeviceApprovals<strong>and</strong>Clearances/Recently-<br />
ApprovedDevices/ucm268836.htm<br />
Accessed 31, Jan 2012<br />
73. Olopade, O.I., Grushko, T.A., N<strong>and</strong>a, R.,<br />
<strong>and</strong> Huo, D. (2008). Advances in breast<br />
cancer: pathways to personalized medicine.<br />
Clin Cancer Res, 14: 7988-99.<br />
74. Pruthi, S., Gostout, B.S., <strong>and</strong> Lindor, N.M.<br />
(2010). Identification <strong>and</strong> management <strong>of</strong><br />
women with BRCA mutations or hereditary<br />
predisposition for breast <strong>and</strong> ovarian<br />
cancer. Mayo Clin Proc, 85: 1111-1120.<br />
75. Hopper, J.L., Chenevix-Trench, G., Jolley,<br />
D.J., Dite, G.S., Jenkins, M.A., Venter, D.J.,<br />
McCredie, M.R., <strong>and</strong> Giles, G.G. (1999).<br />
Design <strong>and</strong> analysis issues in a populationbased,<br />
case-control-family study <strong>of</strong> the